Trial Profile
An open-label study of two single oral doses of galantamine, examining the pharmacokinetics, safety, and tolerability in children with Down syndrome
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 19 Dec 2016
Price :
$35
*
At a glance
- Drugs Galantamine (Primary)
- Indications Down syndrome
- Focus Pharmacokinetics
- Sponsors Janssen-Cilag
- 17 Dec 2016 Status changed from recruiting to discontinued.
- 13 May 2011 New trial record